Designing T-cell engagers for targeting pMHC
09 Feb 2027
Formats & Scaffolds
- How can T-cell engagers effectively target antigens expressed at densities close to the limit of detection?
- How can peptide-centric specificity be achieved while minimising unwanted binding to the MHC backbone?
- How can the challenges of HLA restriction, including a narrower eligible patient population and the potential for tumour escape, be addressed?
- How does loss or alteration of antigen processing contribute to resistance to pMHC-targeting T-cell engagers, and how can this be overcome?
- How can T-cell engagers be designed to achieve an effective therapeutic window while balancing potency, specificity, and safety?
Industry Expert
